Pipeline

Addressing life-threatening, difficult-to-treat solid tumors

A2 Bio’s Pipeline

Our rich pipeline includes one clinical and three pre-clinical programs with different clinically validated solid tumor targets. Tmod™ technology is modular, flexible and compatible with many types of immune cells, as well as manufacturing platforms. A2 Bio is focusing on the use of T cells for our initial pipeline.

Our pipeline

PROGRAM

ACTIVATOR

BLOCKER

INDICATIONS

COMMERCIAL RIGHTS

DISCOVERY

IND-ENABLING

PHASE 1

PHASE 2

AUTOLOGOUS

PROGRAM

ACTIVATOR

CEA

BLOCKER

HLA-A*02

INDICATIONS

Colorectal, Lung and Pancreatic

COMMERCIAL RIGHTS

Discovery

IND-Enabling

Phase1

Phase2


AUTOLOGOUS

PROGRAM

ACTIVATOR

MSLN

BLOCKER

HLA-A*02

INDICATIONS

Ovarian, Mesothelioma, Pancreatic, Colorectal, Lung

COMMERCIAL RIGHTS

Discovery

IND-Enabling

Phase1

Phase2


ALLOGENEIC

PROGRAM

UNDISCLOSED

ACTIVATOR

UNDISCLOSED

BLOCKER

UNDISCLOSED

INDICATIONS

UNDISCLOSED

COMMERCIAL RIGHTS

Discovery

IND-Enabling

Phase1

Phase2


ALLOGENEIC

PROGRAM

UNDISCLOSED

ACTIVATOR

UNDISCLOSED

BLOCKER

UNDISCLOSED

INDICATIONS

UNDISCLOSED

COMMERCIAL RIGHTS

Discovery

IND-Enabling

Phase1

Phase2


ALLOGENEIC

PROGRAM

UNDISCLOSED

ACTIVATOR

UNDISCLOSED

BLOCKER

UNDISCLOSED

INDICATIONS

UNDISCLOSED

COMMERCIAL RIGHTS

Discovery

IND-Enabling

Phase1

Phase2

Programs

Our two lead programs are autologous, followed by three allogeneic candidates.

About A2B530

A2B530 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express carcinoembryonic antigen (CEA) but lack the HLA-A*02 antigen. A2B530 is being studied in our clinical trial EVEREST-1. EVEREST-1 is designed to evaluate patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer (PANC), which are associated with CEA expression.

About A2B694

A2B694 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen.  We intend to evaluate A2B694 in a clinical trial, studying patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PANC), ovarian cancer (OVCA) and mesothelioma, which are associated with MSLN expression.

The modularity of the Tmod™ platform  enables vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations.

Watch how Tmod™ T cells selectively kill tumor cells while sparing normal cells

A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.